Phaseline

Targets › RIF

RIF (Rho-related GTP-binding protein RhoF): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 4; Infectious disease; next expected readout Aug 2029.

Plasma membrane-associated small GTPase which cycles between an active GTP-bound and an inactive GDP-bound state. Causes the formation of thin, actin-rich surface projections called filopodia. (UniProt, Q9HBH0)

Open in Phaseline: the race on RIF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Affiliated Hospital of Nantong UniversityIsoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
INH, RIF, RPTPhase 4Latent Tuberculosis Infection (LTBI)Aug 2029

Conditions

Latent Tuberculosis Infection (LTBI) (2)

Modalities

small molecule (1)

Companies

Affiliated Hospital of Nantong University (1)

Related targets

INH (1) RPT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.